scholarly article | Q13442814 |
meta-analysis | Q815382 |
systematic review | Q1504425 |
review article | Q7318358 |
P819 | ADS bibcode | 2013PLoSO...883022P |
P356 | DOI | 10.1371/JOURNAL.PONE.0083022 |
P932 | PMC publication ID | 3873906 |
P698 | PubMed publication ID | 24386137 |
P5875 | ResearchGate publication ID | 259567616 |
P50 | author | Giovanni Sgroi | Q64786032 |
Fausto Petrelli | Q88397153 | ||
Sandro Barni | Q114372608 | ||
Mary Cabiddu | Q115137157 | ||
Mara Ghilardi | Q115137161 | ||
Andrea Coinu | Q115137170 | ||
P2093 | author name string | Alberto Zaniboni | |
P2860 | cites work | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy | Q83979395 |
Chemotherapy for advanced gastric cancer | Q24236634 | ||
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis | Q30586297 | ||
Aggregate data meta-analysis with time-to-event outcomes | Q30742997 | ||
Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction | Q33380002 | ||
Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. | Q33382794 | ||
S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis | Q33605846 | ||
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients | Q33849656 | ||
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research | Q34581504 | ||
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction | Q34609932 | ||
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 | ||
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer | Q36075265 | ||
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis | Q37845734 | ||
Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials | Q38034487 | ||
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. | Q38059698 | ||
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer | Q45130075 | ||
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study | Q45154773 | ||
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cisplatin | Q412415 |
systematic review | Q1504425 | ||
antineoplastic | Q2853144 | ||
stomach neoplasm | Q4335552 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | e83022 | |
P577 | publication date | 2013-12-27 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis | |
P478 | volume | 8 |
Q53492933 | A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer. |
Q38604012 | Chemotherapy for advanced gastric cancer. |
Q38747484 | FTIR Biospectroscopy Investigation on Cisplatin Cytotoxicity in Three Pairs of Sensitive and Resistant Cell Line |
Q42125510 | Gastric cancer: toward a cisplatin-free disease? |
Q37718510 | Management of advanced gastric cancer: An overview of major findings from meta-analysis. |
Q34444812 | Nephroprotective effect of gelsemine against cisplatin-induced toxicity is mediated via attenuation of oxidative stress |
Q36275825 | Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway |
Q36741735 | Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy |
Q61795899 | The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis |
Q38941416 | The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |
Search more.